Enterprise contract lifecycle management software using AI to extract obligations and risks from contracts
SaaS📍 Bellevue, WAFounded 2009
Current Valuation
$5.0B
as of 2025-Q1
UNICORN
IPO Outlookrumored
Is Icertis going public in 2027?
An IPO is rumored for 2027, with nothing filed. Icertis remains private and the date is not the company's.
What is Icertis' valuation in 2026?
Icertis is valued at $5.0B as of 2025-Q1, set by its Series F (potential sale process) ($50M, Mar 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Icertis filed an S-1?
No public S-1 is on file for Icertis as of 08/23/2026; the IPO is rumored.
Who are Icertis' investors?
Icertis' investors include B Capital Group, Greycroft, Premji Invest, SoftBank, Meritech Capital.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Icertis is the largest pure-play enterprise CLM (contract lifecycle management) vendor with ~$350M ARR, +25% YoY growth, and global enterprise customers including Microsoft, Johnson & Johnson, and Daimler. Last private valuation $5B. As of early 2025 the company has reportedly engaged Goldman Sachs to explore a sale or IPO. Competes with Ironclad and DocuSign CLM in the AI-powered CLM category.
Company Profile
CEO
Samir Bodas
Founded
2009
HQ
Bellevue, WA
Employees
~2500
Total Raised
$525M
Est. Revenue
$350M (2025-FY)
Growth
+25% YoY
Last Round
Series F (potential sale process) — $50M (Mar 2025) · Lead: Goldman Sachs (sale advisor)
IPO Status
rumored
Fundraising Status
Series F (potential sale process) · $50M · 1y 5mo ago
rumoredTotal raised $525M
Secondary Market
Implied price / share
$62.54
Last round price / share
$82.64
vs last round
-24.3%
Open interest
2
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series F (potential sale process)
$50M
Mar 2025
Goldman Sachs (sale advisor)
—
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
12
via careers page
Product-build share
67%
engineering, research, product, design
Trajectory
steady
heavy product build — 67% of open roles are product-building functions (engineering/research/product) — 5 of 12 open roles are research.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Pharmaceutical & Life SciencesMedical DevicesAnalyst & Research Reports[Medical Devices](https://www.icertis.com/solutions/industry-solutions/medical-d[White Papers & eBooks](https://www.icertis.com/research/ebooks/ "White Papers &[The Fine Print](https://www.icertis.com/research/blog/ "The Fine Print")
Counted from Icertis's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Samir BodasMonish Darda
Investors
B Capital Group · Greycroft · Premji Invest · SoftBank · Meritech Capital
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q1. Refreshed quarterly.